Allan M. Jordan

7.8k citations

61 papers · 4.9k indexed · 3 hit papers · h-index 27

Organic Chemistry top 0.5%
Molecular Biology top 2%
Oncology top 5%
Inorganic Chemistry top 2%
Computational Theory and Mathematics top 2%

Co-authors: Stephen D. Roughley Nicholas J. Lawrence Alan T. McGown John A. Hadfield Donald Ogilvie James R. Hitchin Tim C. P. Somervaille Gary J. Spencer
Topics: Epigenetics and DNA Methylation (8 papers)Cancer therapeutics and mechanisms (7 papers)Histone Deacetylase Inhibitors Research (7 papers)
Cited by: Organic Chemistry Molecular Biology Inorganic Chemistry
Journals: Journal of Clinical Oncology Cancer Cell Cancer Research
Partner nations: United Kingdom United States Italy

In The Last Decade

Allan M. Jordan

60 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates

2011 2.2k citations Stephen D. Roughley, Allan M. Jordan profile →
Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle

1998 570 citations Allan M. Jordan, John A. Hadfield et al. Medicinal Research Reviews profile →
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells

2012 432 citations William J. Harris, Xu Huang et al. Cancer Cell profile →

Peers

Countries citing papers authored by Allan M. Jordan

Since Specialization

Citations

This map shows the geographic impact of Allan M. Jordan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan M. Jordan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan M. Jordan more than expected).

Fields of papers citing papers by Allan M. Jordan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan M. Jordan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan M. Jordan. The network helps show where Allan M. Jordan may publish in the future.

Co-authorship network of co-authors of Allan M. Jordan

This figure shows the co-authorship network connecting the top 25 collaborators of Allan M. Jordan. A scholar is included among the top collaborators of Allan M. Jordan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan M. Jordan. Allan M. Jordan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The severity of SARS‐CoV‐2 infection in K18‐hACE2 mice is attenuated by a novel steroid‐derivative in a gender‐specific manner 2023 ·British Journal of Pharmacology ·Sachin A. Gupte,Chandra Shekhar Bakshi,(unknown),G Duhamel,Allan M. Jordan,Padmini Salgame,(unknown),Mohammad Yahiya Khan,Jerry L. Nadler,(unknown)	2
2	Molecularly profiled trials: toward a framework of actions for the “nil actionables” 2021 ·British Journal of Cancer ·Allan M. Jordan	1
3	Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia 2018 ·Cell Reports ·Alba Maiqués-Díaz,Gary J. Spencer,James T. Lynch,Filippo Ciceri,Emma L. Williams,Fabio M. R. Amaral,Daniel H. Wiseman,William J. Harris,Yaoyong Li,Sudhakar Sahoo,James R. Hitchin,Daniel P. Mould,Emma Fairweather,Bohdan Waszkowycz,Allan M. Jordan,Duncan L. Smith,Tim C. P. Somervaille	137
4	Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling 2017 ·Annals of Oncology ·Avinash Gupta,Mahmood Ayub,Crispin Miller,Dominic G. Rothwell,Andrew Wallace,Allan M. Jordan,Natalie Cook,Fiona Thistlethwaite,(unknown),Ciara O’Brien,(unknown),Emma Dean,Andrew Hudson,(unknown),(unknown),Andrew Hughes,Richard Marais,Caroline Dive,Gerard Brady,Matthew Krebs	3
5	Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1 2017 ·Bioorganic & Medicinal Chemistry Letters ·Daniel P. Mould,Ulf Bremberg,Allan M. Jordan,Matthis Geitmann,Alba Maiqués-Díaz,Alison E. McGonagle,Helen Small,Tim C. P. Somervaille,Donald Ogilvie	13
6	Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1 2017 ·Bioorganic & Medicinal Chemistry Letters ·Daniel P. Mould,Ulf Bremberg,Allan M. Jordan,Matthis Geitmann,Alison E. McGonagle,Tim C. P. Somervaille,Gary J. Spencer,Donald Ogilvie	10
7	Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position 2016 ·Bioorganic & Medicinal Chemistry Letters ·Allan M. Jordan,(unknown),Emma Fairweather,(unknown),Kristin Goldberg,(unknown),Niall M. Hamilton,Amanda Lyons,H. Nikki March,Rebecca Newton,Helen Small,(unknown),Ian D. Waddell,Bohdan Waszkowycz,Amanda J. Watson,Donald Ogilvie	10
8	Torin1 mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells 2014 ·Journal of Cell Science ·(unknown),(unknown),Jennifer Ferguson,James R. Hitchin,Agata Lichawska-Cieślar,Allan M. Jordan,Jonathon Pines,Claudia Wellbrock,Janni Petersen	37
9	The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells 2012 ·Cancer Cell ·(unknown),Xu Huang,James T. Lynch,James R. Hitchin,Yaoyong Li,Filippo Ciceri,(unknown),Brigit Greystoke,Allan M. Jordan,Donald Ogilvie,Tim C. P. Somervaille	15
10	The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cellsbreakdown → 2012 ·Cancer Cell ·William J. Harris,Xu Huang,James T. Lynch,Gary J. Spencer,James R. Hitchin,Yaoyong Li,Filippo Ciceri,(unknown),Brigit Greystoke,Allan M. Jordan,Crispin Miller,Donald Ogilvie,Tim C. P. Somervaille	432
11	Antagonists of the human A2A receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides 2009 ·Bioorganic & Medicinal Chemistry Letters ·Roger J. Gillespie,(unknown),Suneel Gaur,Allan M. Jordan,Joanne Lerpiniere,Howard L. Mansell,(unknown)	23
12	Antagonists of the human A2A receptor. Part 6: Further optimization of pyrimidine-4-carboxamides 2009 ·Bioorganic & Medicinal Chemistry ·Roger J. Gillespie,(unknown),(unknown),Suneel Gaur,(unknown),Philip S. Jackson,Allan M. Jordan,Burkhard Klenke,(unknown),(unknown),Howard L. Mansell,Sean Y. Ng,(unknown),Heather Simmonite,(unknown),Richard S. Todd,D.S. Williamson,(unknown)	27
13	Drug discovery chemistry: a primer for the non-specialist 2009 ·Drug Discovery Today ·Allan M. Jordan,Stephen D. Roughley	35
14	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines 2008 ·Bioorganic & Medicinal Chemistry Letters ·Roger J. Gillespie,Ian A. Cliffe,Claire Dawson,Colin T. Dourish,Suneel Gaur,Allan M. Jordan,Antony R. Knight,Joanne Lerpiniere,Anil Kumar Misra,Robert M. Pratt,(unknown),(unknown),Rebecca Upton,Scott Μ. Weiss,D.S. Williamson	55
15	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives 2008 ·Bioorganic & Medicinal Chemistry Letters ·Roger J. Gillespie,Ian A. Cliffe,Claire Dawson,Colin T. Dourish,Suneel Gaur,Paul R. Giles,Allan M. Jordan,Antony R. Knight,Anthony J. Lawrence,Joanne Lerpiniere,Anil Kumar Misra,Robert M. Pratt,Richard S. Todd,Rebecca Upton,Scott Μ. Weiss,D.S. Williamson	24
16	Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches 2006 ·Bioorganic & Medicinal Chemistry Letters ·Christine M. Richardson,Roger J. Gillespie,D.S. Williamson,Allan M. Jordan,Alexandra Fink,Antony R. Knight,(unknown),Anil Kumar Misra	17
17	4-Amino derivatives of the Hsp90 inhibitor CCT018159 2006 ·Bioorganic & Medicinal Chemistry Letters ·Xavier Barril,Mandy Beswick,Adam J. Collier,Martin J. Drysdale,Brian Dymock,Alexandra Fink,(unknown),Robert I. Howes,Allan M. Jordan,Andrew J. Massey,A.E. Surgenor,(unknown),Paul Workman,Lisa Wright	67
18	Melanocyte-Directed enzyme prodrug therapy (MDEPT) 2001 ·Bioorganic & Medicinal Chemistry ·Allan M. Jordan,Tariq H Khan,(unknown),Helen M. I. Osborn,Α. Φωτίου,Patrick A. Riley	41
19	Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma 1999 ·Bioorganic & Medicinal Chemistry ·Allan M. Jordan,Tariq H Khan,Helen M. I. Osborn,Α. Φωτίου,Patrick A. Riley	39
20	Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindlebreakdown → 1998 ·Medicinal Research Reviews ·Allan M. Jordan,John A. Hadfield,Nicholas J. Lawrence,Alan T. McGown	570

About Allan M. Jordan

Allan M. Jordan is a scholar working on Physiology, Molecular Biology and Oncology, having authored 61 papers that have together received 4.9k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (8 papers), Cancer therapeutics and mechanisms (7 papers) and Histone Deacetylase Inhibitors Research (7 papers). The work is most often cited by research in Organic Chemistry (2.7k citations), Molecular Biology (2.5k citations) and Inorganic Chemistry (500 citations). Allan M. Jordan has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Stephen D. Roughley, Nicholas J. Lawrence, Alan T. McGown, John A. Hadfield, Donald Ogilvie, James R. Hitchin, Tim C. P. Somervaille, Gary J. Spencer, Daniel P. Mould and Yaoyong Li. Their work appears in journals such as Journal of Clinical Oncology, Cancer Cell and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact